STAT+: Pharmalittle: Novartis reorganizes and hopes to save $1 billion; industry-backed antibiotic fund makes first investments
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
Category: Pharmalot
STAT+: Pharma’s ambitious new antibiotic venture fund makes its first investments
One year after its splashy launch, the AMR Action Fund has made its first investments…
.jpg)
STAT+: Pharmalittle: Califf admits Alzheimer’s drug controversy has hurt expert trust in FDA; House passes bill to lower insulin costs
And so, another working week will soon draw to a close. Not a moment too…
STAT+: In the wake of Covid, a World Health Assembly proposal would bolster quality of clinical trials
Ahead of a World Health Assembly meeting in May, the United Kingdom is circulating a…
STAT+: Pharmalittle: Advisory panel narrowly votes down ALS drug; Vertex looks to advance experimental pain drug
Good morning. Elizabeth Cooney here, borrowing the virtual Pharmalittle chair while Ed Silverman takes Manhattan…
STAT+: Pharma companies face shareholder proposals to widen access to medicines, rework business plans
Over the next few weeks, several major pharmaceutical companies will face a fresh crop of…
STAT+: CVS, Teva, and Allergan reach massive deal with Florida over the opioid crisis
On the eve of a trial, the state of Florida has reached a massive settlement…
.jpg)
STAT+: Pharmalittle: Roche immunotherapy fails its first test; key U.S. senators move closer to bill to cap insulin prices
Hello, everyone, and how are you this fine, sunny morning? The middle of the week…
STAT+: HHS seeks to penalize another drugmaker amid legal clash over drug discount program
The U.S. Health and Resources Administration is seeking to penalize Boehringer Ingelheim for curtailing discounts…
STAT+: Inflation caused ‘unprecedented’ drops in net pharmaceutical prices, analysis finds
Amid ongoing turmoil over the cost of prescription medicines, a new analysis finds that brand-name…
STAT+: Pharmalittle: Pfizer employees balk at returning overpayments; Biogen stops work on another ALS drug
Rise and shine, everyone, another busy day is on the way. This morning is getting…
STAT+: Pharmalittle: Pharma showers cash on a rising U.S. Senate star; FDA restricts use of a Glaxo Covid treatment
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Pharmalittle: Pharma hunts for a cure for long Covid; Texas AG deepens puberty-blocker probe into AbbVie and Endo
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Despite competition, U.S. cancer drug prices rose even as they fell in Germany and Switzerland
Even as prices rose substantially in the U.S. over a recent 12-year period, a new…
STAT+: Sun Pharmaceuticals to pay $485 million to settle claims its Ranbaxy unit caused customers to overpay for generics
On the eve of a trial, Sun Pharmaceuticals has agreed to pay $485 million to…
STAT+: Pharmalittle: FDA rejects Lilly drug studied only in China; AstraZeneca suffers a setback with a key cancer drug
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Pharmalittle: Moderna asks FDA to OK Covid shot for kids under 6; big generic maker to close U.S. plant
Top of the morning to you. Another busy day is unfolding here on the Pharmalot…
STAT+: Aurobindo, major generic drug maker, will close a key U.S. production plant
Aurobindo Pharma, which is based in India and is one of the largest global producers…
STAT+: Pharmalittle: FDA faces immense pressure over an ALS drug; former Biogen R&D chief seeks a reset at another biotech
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: Pfizer inks deal with UNICEF to supply Covid pill to poor countries, but advocates say it isn’t enough
As part of an effort to widen access to its Covid-19 pill, Pfizer has reached…
STAT+: ‘Harmful and wasteful’: Many pediatric clinical trials end early or don’t report results
An extensive analysis of thousands of pediatric trials found one in 10 ended early —…
STAT+: Teva and Allergan reach $107 million deal with Rhode Island over opioid crisis
Just as a trial was getting underway, AbbVie and Teva Pharmaceutical reached a settlement worth…
STAT+: Pharmalittle: Covid-19 vaccine market is getting crowded as demand wanes; Russia looks to India to supply pharmaceuticals
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: When should drugmakers go all in and cut off essential medicines to Russia?
Just say nyet? As the war in Ukraine intensifies, several of the world’s largest pharmaceutical…
STAT+: Pharmalittle: Lawmakers face off over FDA’s accelerated approval; ivermectin failed to reduce Covid-19 hospital admissions
And so, another working week will soon draw to a close. This is, as you…
STAT+: Alnylam sues Pfizer and Moderna for patent infringement in development of Covid-19 vaccines
Alnylam Pharmaceuticals has filed separate lawsuits alleging that Pfizer and Moderna infringed its patents in…
STAT+: Pharmalittle: Biogen Alzheimer’s data is published in little-known journal; WHO may reject Medicago Covid shot over ties to Philip Morris
Good morning, everyone, and how are you today? A spot of rain is descending on…
STAT+: A battle is brewing between a senator and a nonprofit over pharma patenting practices
As the pharmaceutical industry faces pointed criticism over its patent practices, an effort appears to…
STAT+: Pharmalittle: Compromise reached on Covid-19 vaccine patent waivers; Biogen reports upbeat data on its Alzheimer’s drug
Hello, everyone, and welcome to the middle of the week. You made it this far,…
STAT+: Lawmakers accuse PhRMA of providing ‘misleading information’ about drug price hikes
A group of Congressional lawmakers is accusing the pharmaceutical industry’s leading trade group of providing…
STAT+: A compromise is reached on an intellectual property waiver for Covid-19 vaccines, but does it go far enough?
After 18 months of talks, a compromise was reached on a proposal to waive intellectual…
STAT+: Gilead faces criticism for donations to state senators who backed ‘Don’t Say Gay’ bill in Florida
There was a curious dichotomy underlying the outcry over the so-called ‘Don’t Say Gay’ bill…
STAT+: Pharmalittle: Congress wants opioid-settlement tax breaks probed; another yawner of a drug-pricing hearing?
Hello, everyone, and how are you today? A shiny sun is warming the Pharmalot campus,…
STAT+: Arrowhead shareholders urged not to approve ‘excessive’ compensation for non-executive directors
In an unusual move, a prominent shareholder advisory firm is urging investors in Arrowhead Pharmaceuticals…
STAT+: Watcdog says Lilly made ‘false assertions’ about impact of pausing political donations after Jan. 6 attack
Early last year, Eli Lilly (LLY) temporarily halted contributions made to members of Congress who…
STAT+: Pharmalittle: Patient groups pressure Medicare over Alzheimer’s drug; pharma says it’s duty-bound to sell meds in Russia
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: Cutting-edge gene therapies could be coming for sickle cell. Will Medicaid patients be able to access them?
Gary Puckrein sees a dilemma coming that has him excited, and at the same time,…
STAT+: Pharmalittle: Opioid victims and their families berate Sacklers in court hearing; Glaxo shingles vaccine campaign in U.K. is criticized
And so, another working week will soon draw to a close. Not a moment too…
STAT+: Pharmalittle: Bankruptcy court judge OKs Purdue settlement; U.S. Senate revives legislation to curb insulin costs
Rise and shine, another busy day is on the way. However, this is also shaping…
STAT+: Dozens of towns and counties object to ‘hush money’ tied to Purdue opioid settlement
Ahead of a bankruptcy court hearing to approve a $6 billion settlement with Purdue Pharma…
STAT+: Pharmalittle: Insurers balk at opioid payouts to drugmakers and wholesalers; AbbVie settles another Humira biosimilar lawsuit
Good morning, everyone, and how are you today? We are doing just fine, thank you,…
STAT+: AbbVie settles litigation with another drug maker over a biosimilar version of Humira
After months of squabbling over allegedly stolen trade secrets, AbbVie (ABBV) has settled litigation with…
STAT+: Mallinckrodt to pay $260 million to settle federal lawsuits over Medicaid rebates and kickbacks
After years of squabbling, Mallinckrodt agreed to pay $260 million to settle accusations that it…
STAT+: Pharmalittle: U.S. lawmaker proposes bill to curtail FDA’s accelerated approval; Moderna to enforce Covid patents in wealthy countries
Top of the morning to you. A shiny sun is enveloping the Pharmalot campus this…
STAT+: Moderna looks to enforce its Covid-19 vaccine patents in wealthy countries
Amid intense public pressure, Moderna (MRNA) updated a pledge not to enforce patents for its…
STAT+: FDA effort to improve clinical trial diversity failed to make a difference for Black patients, study finds
Six years ago, the U.S. Food and Drug Administration launched a five-year action plan to…
STAT+: Few public biotech companies disclose environmental, social, and governance steps
Environmental, social, and governance issues are gaining greater attention among investors, but only 30% of…
STAT+: Pharmalittle: White House bid for Covid drug funding hurt by transparency issue; Bluebird Bio runs short of cash
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT+: An international treaty is needed to prevent countries from banning exports of medical products, experts urge
Amid increasing concern over shortages of medical products, a new study recommends that the United…
STAT+: ViiV causes an outcry by declining to pursue voluntary licensing for its HIV prevention shot
In a surprise move, ViiV Healthcare has decided not to license its long-acting injectable HIV…